Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
HER2 Testing: Insights From Pathologists' Perspective on Technically Challenging HER2 FISH Cases.
Appl Immunohistochem Mol Morphol. 2021 Oct 1;29(9):635-642. doi: 10.1097/PAI.0000000000000946.
Appl Immunohistochem Mol Morphol. 2021.
PMID: 34282066
Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML, Lillemoe TJ, Finkelstein MJ, Money JE, Susnik B, Grimm E, Kang SH, Swenson KK.
Tsai ML, et al.
Clin Breast Cancer. 2016 Feb;16(1):45-50. doi: 10.1016/j.clbc.2015.08.001. Epub 2015 Aug 19.
Clin Breast Cancer. 2016.
PMID: 26385397
Item in Clipboard
Pathologic Predictors of Treatment Response to Neo-adjuvant Chemotherapy for Invasive Lobular Breast Carcinoma.
Tsai M, Finkelstein M, Lillemoe T, Susnik B, Grimm E, Kang SH, Kelly C, Swenson K.
Tsai M, et al.
Breast J. 2017 Sep;23(5):607-609. doi: 10.1111/tbj.12809. Epub 2017 Mar 22.
Breast J. 2017.
PMID: 28328042
No abstract available.
Item in Clipboard
Clinicopathologic analysis of a large series of microinvasive breast cancers.
Lillemoe TJ, Tsai ML, Swenson KK, Susnik B, Krueger J, Harris K, Rueth N, Grimm E, Leach JW.
Lillemoe TJ, et al.
Breast J. 2018 Jul;24(4):574-579. doi: 10.1111/tbj.13001. Epub 2018 Feb 24.
Breast J. 2018.
PMID: 29476574
Item in Clipboard
Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-related Characteristics, and Pregnancy-associated Diagnosis on Outcomes.
Tsai ML, Knaack M, Martone P, Krueger J, Baldinger SR, Lillemoe TJ, Susnik B, Grimm E, Olet S, Rueth N, Swenson KK.
Tsai ML, et al.
Clin Breast Cancer. 2021 Feb;21(1):47-56. doi: 10.1016/j.clbc.2020.07.003. Epub 2020 Jul 9.
Clin Breast Cancer. 2021.
PMID: 32739136
Item in Clipboard
HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Lillemoe TJ, Rendi M, Tsai ML, Knaack M, Yarosh R, Grimm E, Susnik B, Krueger J, Olet S, Swenson KK.
Lillemoe TJ, et al.
Int J Breast Cancer. 2021 May 24;2021:6684629. doi: 10.1155/2021/6684629. eCollection 2021.
Int J Breast Cancer. 2021.
PMID: 34123431
Free PMC article.
Item in Clipboard
Cite
Cite